Skip to main content

Table 1 Characterization of Afa/LPN and peptide-modified LPNs

From: Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model

Formulations Particle size (nm) PdIa Zeta potential (mV) EE%b
LPN 145.26 ± 2.48 0.20 ± 0.04 − 15.28 ± 2.16 –
Afa/LPN 168.61 ± 4.10 0.22 ± 0.03 − 13.83 ± 0.49 87.52 ± 1.72
Afa/LPN-FD7 166.12 ± 8.91 0.21 ± 0.02 − 10.74 ± 1.42 87.33 ± 1.54
Afa/LPN-CCD 150.18 ± 0.31 0.23 ± 0.03 −  25.32 ± 1.50 86.83 ± 1.62
  1. aPdI polydispersity index
  2. bEE% encapsulation efficiency
Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us